PCAS: 1st Half 2020 Earnings Report
08 Settembre 2020 - 8:51PM
PCAS: 1st Half 2020 Earnings Report
Ecully, September 8, 2020
1st HALF 2020 EARNINGS
REPORT
PCAS (Euronext Paris: PCA), a
specialist in the development and production of complex molecules
for life sciences and innovative technologies, has announced the
publication of its consolidated earnings for the first half of
2020.
|
|
|
|
|
|
|
|
|
|
|
|
30 June 2019 |
|
30 June 2020 |
|
|
in millions of euros |
|
|
|
|
|
|
|
|
|
|
|
|
Net
sales |
|
102.3 |
|
105.1 |
|
|
|
|
|
|
|
|
|
|
EBITDA
(*) |
|
7.2 |
|
7.2 |
|
|
|
EBITDA margin |
|
7.1% |
|
6.9% |
|
|
|
|
|
|
|
|
|
|
Current operating
income (*) |
|
-1.5 |
|
-3.0 |
|
|
|
|
|
|
|
|
|
|
Other operating income and
expenses |
|
-5.4 |
|
-0.2 |
|
|
|
|
|
|
|
|
|
|
Operating
income |
|
-6.9 |
|
-3.2 |
|
|
|
|
|
|
|
|
|
|
Financial result |
|
-0.7 |
|
-1.5 |
|
|
Taxes |
|
-1.2 |
|
-1.1 |
|
|
|
|
|
|
|
|
|
|
Net
result |
|
-8.7 |
|
-5.8 |
|
|
|
|
|
|
|
|
|
|
(*) of which research tax credit (CIR): 2.2 M€ in 2019 and 2.1 M€
in 2020 |
|
|
Results
The PCAS Group has generated consolidated net
sales of €105.1 million as of June 30, 2020, representing an
increase of 2.8% compared to the same period in the previous
financial year (+2.2% at a constant exchange rate).
EBITDA reaches €7.2 million at June 30,
2020, same amount as last year. The current operating income is
down to -€3.0 million at June 30, 2020, as a result of higher
depreciation incurred by a higher investment program implemented to
develop projects that aim to increase the Group's business levels
in the coming years.
Net income totaled -€5.8 million in the
first half year of 2020, as against -€8.7 million at June 30,
2019. For the record, other operating income and expenses in 2019
included a net expense of €3.8 million concerning the
Longjumeau site reorganization plan.
Outlook
As stated in our press releases of March 31,
2020 and July 23, 2020, the global health crisis relating to the
Covid-19 is changing everyday, and there are still uncertainties
regarding its duration, its extent and its effects on companies'
production lines and consumption in general.
The PCAS Group has not seen any significant
impacts on its business activities and earnings, except for the
delay in the commissioning of the new production unit in
Villeneuve-la-Garenne, now planned for October 2020. The delayed
commissioning of this production unit will have the effect of
carrying forward approximately €5 million of net sales to
2021. Furthermore, some activities (lubricants and fine chemicals,
for which the end markets are mainly automotive and construction)
have recorded significant drops in demand. However, it is still
hard to anticipate the potential impacts in the medium term. This
crisis calls for cautious measures, and due to these exceptional
circumstances, the Group has suspended its financial targets and
its strategic business objectives until the situation becomes
clearer.
NEXT FINANCIAL DISCLOSURE:
2020 3rd quarter net sales, on November 5,
2020.
ABOUT PCAS
PCAS specializes in the development and
production of complex molecules for life sciences and innovative
technologies. With 10% of its net sales earmarked for R&D and a
large international footprint, PCAS is the preferred industrial
partner for market-leading major global groups. Boasting especially
high standards, the company offers a growing range of proprietary
products and solutions in leading-edge segments. PCAS generated net
sales of €200.9 million in 2019 and employs close to 1 100
people in six countries.
To find out more about PCAS: www.pcas.com
PCAS |
Newcap |
Pierre Luzeau / Eric Moissenot |
Emmanuel Huynh / Louis-Victor Delouvrier
NewCapFinancial communication and investor |
Tél. : +33 1 69 79 60 00www.pcas.com |
Tél. : +33 1 44 71 98 53pcas@newcap.eu |
- PCAS - Communiqué de presse - Résultats du 1er semestre
2020_en-US Vdef
Grafico Azioni PCAS (EU:PCA)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni PCAS (EU:PCA)
Storico
Da Mag 2023 a Mag 2024